Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II oral metformin marker-lesion study in non-muscle-invasive bladder cancer
NL-OMON56329Phase 2Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of metformin in bladder cancer and non-muscle-invasive bladder cancer (NMIBC), sponsored by Amsterdam University Medical Center. Primary endpoint: Complete response rate. Started Apr 2019; status: active, not recruiting.
02
Drugs
metformin
03
Conditions
bladder cancernon-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NL-OMON56329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56329.